HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Groups Take Lead In Outing Drug Disguised As Dietary Supplement

This article was originally published in The Rose Sheet

Executive Summary

Four groups say drug identified as “phenibut” is being used in products fraudulently labeled as supplements. The drug, reportedly developed in the former Soviet Union for brain-enhancing properties, has been found in products typically marketed for cognitive benefit and mood enhancement."We're not going to wait for someone to tell us this is not a dietary ingredient," says CRN executive Duffy MacKay.

You may also be interested in...



US Supplement Firm Warned About Phenibut After Failing To Pull PTSD, Detox, Anxiety Claims

Latest FDA warning to Chill6 doesn’t reference previous letter but lists larger number of violations along with more details about the problems. Agency also recently added salt scrub therapies to its list of products as marketed with fraudulent coronavirus treatment claims.

Opioid Treatment Claims Linked To Depression Drug Found In Supplements

FDA warns MA Labs and Jack B Goods about online claims that their tianeptine-containing products treat opioid use disorder, pain and anxiety and other violative and unproven claims. CDC reports a jump in poison control center reports on tianeptine, which is approved outside the US to treat depression.

Health, Beauty And Wellness News: Nestle Compleat, FDA Nutrition Strategy

Supplement OWL sports CDX; FDA schedules Nutrition Strategy meeting, improves food substances inventory; Innotech imports Wholy Tea to US; Thorne adds Bommarito to exclusive provider list; and Nestle Compleat line blended for tube-feeding.

Related Content

Topics

UsernamePublicRestriction

Register

RS122410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel